Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lei Liu
Institution:
Xuzhou Medical College
Observed institutions:
University of Electronic Science and Technology of China,
Xuzhou Medical College,
Sichuan Cancer Hospital
ORCID:
0000-0001-5918-9774
Observed ORCID:
0000-0001-5918-9774
OpenAlex ID:
A5052249181
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
2025
·
Xiaoxiao Liu
, Chunying Zhuang
, et al.
·
Signal Transduction and Targeted Therapy
·
15
PDF
Patient‑reported outcome measures for assessing health‑related quality of life in patients with differentiated thyroid cancer: a systematic review
2024
·
Lujing Xiong
, Lei Liu
, et al.
·
International Journal of Surgery
·
4
Long‐term follow‐up and prognostic analysis of parotid tumors in children and adolescents
2024
·
Lei Liu
, Yuqing Xiang
, et al.
·
Laryngoscope Investigative Otolaryngology
·
1
Show more works
View as search
Works count:
3
Citation count:
20
H-index:
2
I10-index:
1
Year
Topic
Type